Elli Kruithof

Randomized double‐blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondylarthropathy

Filip Van den Bosch, Elli Kruithof, Dominique Baeten et al. · Arthritis & Rheumatism · 2002 · 355 citations

Life Sciences, Immunology, Pharmacotherapy +13

Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondyloarthropathy: an open pilot study

Filip Van den Bosch, Elli Kruithof, Dominique Baeten et al. · Annals of the Rheumatic Diseases · 2000 · 292 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +13

Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis

Elli Kruithof, Dominique Baeten, Leen De Rycke et al. · Arthritis Research & Therapy · 2005 · 261 citations · Full text

Medicine, Pathology, Histopathology +16

Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy

Leen De Rycke, Elli Kruithof, Nancy Van Damme et al. · Arthritis & Rheumatism · 2003 · 222 citations

Life Sciences, Immunology, Internal Medicine +17

Immunomodulatory effects of anti-tumor necrosis factor ? therapy on synovium in spondylarthropathy: Histologic findings in eight patients from an open-label pilot study

Dominique Baeten, Elli Kruithof, Filip Van den Bosch et al. · Arthritis & Rheumatism · 2001 · 188 citations

Medicine, Immunology, Pathology +17